Full Breakdown
Nationwide Recall of Blood Pressure Medication Due to Contamination
12/9/2025, 10:53:48 AM
Overview of the Recall
On December 1, 2025, the U.S. Food and Drug Administration (FDA) announced a nationwide recall of approximately 11,100 bottles of the blood pressure medication bisoprolol fumarate and hydrochlorothiazide, marketed under the brand name Ziac. The recall was initiated by Glenmark Pharmaceuticals, based in Elmwood Park, New Jersey, after testing revealed trace amounts of ezetimibe, a drug used to treat high cholesterol, in reserve samples of the medication.
Details of the Affected Products
The recall encompasses various bottle sizes of Ziac, specifically 30-count bottles (NDC 68462-878-30), 100-count bottles (NDC 68462-878-01), and 500-count bottles (NDC 68462-878-05). The affected tablets are available in dosages of 2.5 mg and 6.25 mg, with expiration dates ranging from November 2025 to May 2026. The FDA classified this recall as Class III, indicating that exposure to the contaminated product is "not likely to cause adverse health consequences."
Official Statements & Responses
The FDA has not provided specific guidance on how consumers should handle the recalled medication. Glenmark Pharmaceuticals has also not issued a statement regarding the recall or recommendations for consumers who may have purchased the affected products.
Criticism & Opposition
There has been concern among healthcare professionals regarding the implications of cross-contamination in pharmaceutical products. Critics argue that even trace amounts of a different medication could pose risks, particularly for patients with specific health conditions or those who are sensitive to certain drugs. The lack of immediate guidance from Glenmark and the FDA has also drawn scrutiny, as patients may be left uncertain about the safety of their medications.
Conflicting Reports & Gaps
While the recall affects approximately 11,100 bottles, some reports vary slightly in the exact number of affected units. Additionally, there is no information available on the potential impact of this contamination on patients who have already consumed the medication. The absence of clear instructions for consumers adds to the uncertainty surrounding the recall.
Verbatim Quotes
- “This means the use or exposure to the recalled product “is not likely to cause adverse health consequences,” according to the FDA.” — FDA Statement
- “Testing revealed that "trace amounts of ezetimibe," a prescription drug used to treat high cholesterol, were detected in reserve samples.” — FDA Announcement
This recall highlights the importance of rigorous testing and quality control in the pharmaceutical industry to prevent cross-contamination and ensure patient safety.
